Longitude Capital
Dr. Liu is a Principal at Longitude Capital. Prior to joining Longitude Capital in 2018, Dr. Liu was an Engagement Manager in the pharmaceuticals and medical products practice of McKinsey & Company. Dr. Liu currently serves on the board of CG Oncology and is a board observer at Quanta Therapeutics, Rivus Pharmaceuticals, and Zenas Biopharma. He previously served as a board observer at Dascena, Endeavor Biomedicines, Inflazome (acquired by Roche), Talaris Therapeutics (TALS), and Vera Therapeutics (VERA), and was also actively involved in Longitude Capital’s investment in Strongbridge Biopharma (SBBP). Dr. Liu holds an MD from Stanford School of Medicine and a BS in Biomedical Engineering from The Johns Hopkins University.
This person is not in any teams
Longitude Capital
Longitude Capital specializes in making venture growth investments in biotechnology, medical technology and health solutions companies that seek to improve clinical outcomes, enhance quality of life and/or reduce system costs. Longitude Capital invests in both privately held and publicly traded life science companies through a variety of investment approaches.